FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3072257851> ?p ?o ?g. }

• W3072257851 endingPage "1043" @default.
• W3072257851 startingPage "1043" @default.
• W3072257851 abstract "<h3>Importance</h3> When initiating anti–vascular endothelial growth factor (VEGF) treatment for patients with neovascular age-related macular degeneration (nAMD), knowledge of prognostic factors is important for advising patients and guiding treatment. We hypothesized that eyes with greater fluctuation in retinal thickness over time have worse outcomes than eyes with less variation. <h3>Objective</h3> To investigate whether visual and anatomic outcomes in eyes with nAMD initiating anti-VEGF treatment are associated with fluctuations in retinal thickness. <h3>Design, Setting, and Participants</h3> In this study using data from the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and the Inhibition of VEGF in Age-Related Choroidal Neovascularization (IVAN) randomized clinical trial, people with previously untreated nAMD were included. Data were collected from February 2008 to November 2012, and data were analyzed from April 2017 to April 2020. <h3>Main Outcomes and Measures</h3> Foveal center point thicknesses (FCPTs) were extracted from 1165 study eyes from CATT and 566 study eyes from the IVAN trial, excluding those with 3 measurements or less. For each eye, the SD of FCPT was calculated. Eyes were grouped by FCPT SD quartile. Associations of FCPT SD quartile with outcomes were quantified at month 24 or the last available visit by linear or logistic regression, adjusting for baseline best-corrected visual acuity (BCVA) and randomized allocations to drug and treatment regimen, for BCVA, development of fibrosis, and development of macular atrophy. <h3>Results</h3> Of the 1731 included patients, 1058 (61.1%) were female, and the mean (SD) age was 78.6 (7.4) years. The median (interquartile range) FCPT SD was 40.2 (27.1-61.2) in the IVAN cohort and 59.0 (38.3-89.4) in the CATT cohort. After adjustment for baseline BCVA and trial allocations, BCVA worsened significantly across the quartiles of FCPT SD; the difference between the first and fourth quartiles was −6.27 Early Treatment Diabetic Retinopathy Study letters (95% CI, −8.45 to −4.09). The risk of developing fibrosis and macular atrophy also increased across FCPT SD quartiles. Odds ratios ranged from 1.40 (95% CI, 1.03 to 1.91) for quartile 2 to 1.95 (95% CI, 1.42 to 2.68) for quartile 4 for fibrosis and from 1.32 (95% CI, 0.90 to 1.92) for quartile 2 to 2.10 (95% CI, 1.45 to 3.05) for quartile 4 for macular atrophy. <h3>Conclusions and Relevance</h3> Greater variation in retinal thickness in eyes with nAMD during treatment with anti-VEGF was associated with worse BCVA and development of fibrosis and macular atrophy in these post hoc analyses, despite protocol-directed treatment frequency. Practitioners may want to consider variation in retinal thickness when advising patients about their prognosis." @default.
• W3072257851 created "2020-08-24" @default.
• W3072257851 creator A5006959216 @default.
• W3072257851 creator A5007945636 @default.
• W3072257851 creator A5008059536 @default.
• W3072257851 creator A5018227698 @default.
• W3072257851 creator A5019521414 @default.
• W3072257851 creator A5020800294 @default.
• W3072257851 creator A5054954472 @default.
• W3072257851 creator A5091736159 @default.
• W3072257851 date "2020-10-01" @default.
• W3072257851 modified "2023-10-14" @default.
• W3072257851 title "Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti–Vascular Endothelial Growth Factor Agents" @default.
• W3072257851 cites W1481978003 @default.
• W3072257851 cites W1500728559 @default.
• W3072257851 cites W1935342590 @default.
• W3072257851 cites W1986457383 @default.
• W3072257851 cites W2020008658 @default.
• W3072257851 cites W2063028754 @default.
• W3072257851 cites W2074575505 @default.
• W3072257851 cites W2093646832 @default.
• W3072257851 cites W2096097549 @default.
• W3072257851 cites W2102946567 @default.
• W3072257851 cites W2104208472 @default.
• W3072257851 cites W2108445835 @default.
• W3072257851 cites W2132899855 @default.
• W3072257851 cites W2146673937 @default.
• W3072257851 cites W2154073405 @default.
• W3072257851 cites W2266679784 @default.
• W3072257851 cites W2467975538 @default.
• W3072257851 cites W2545082692 @default.
• W3072257851 cites W2584295152 @default.
• W3072257851 cites W2609395803 @default.
• W3072257851 cites W2753708825 @default.
• W3072257851 cites W2766256148 @default.
• W3072257851 cites W2788454982 @default.
• W3072257851 cites W2804532233 @default.
• W3072257851 cites W2891521689 @default.
• W3072257851 cites W2895700191 @default.
• W3072257851 cites W2910898668 @default.
• W3072257851 cites W2965769306 @default.
• W3072257851 doi "https://doi.org/10.1001/jamaophthalmol.2020.3001" @default.
• W3072257851 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7441468" @default.
• W3072257851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32816002" @default.
• W3072257851 hasPublicationYear "2020" @default.
• W3072257851 type Work @default.
• W3072257851 sameAs 3072257851 @default.
• W3072257851 citedByCount "60" @default.
• W3072257851 countsByYear W30722578512020 @default.
• W3072257851 countsByYear W30722578512021 @default.
• W3072257851 countsByYear W30722578512022 @default.
• W3072257851 countsByYear W30722578512023 @default.
• W3072257851 crossrefType "journal-article" @default.
• W3072257851 hasAuthorship W3072257851A5006959216 @default.
• W3072257851 hasAuthorship W3072257851A5007945636 @default.
• W3072257851 hasAuthorship W3072257851A5008059536 @default.
• W3072257851 hasAuthorship W3072257851A5018227698 @default.
• W3072257851 hasAuthorship W3072257851A5019521414 @default.
• W3072257851 hasAuthorship W3072257851A5020800294 @default.
• W3072257851 hasAuthorship W3072257851A5054954472 @default.
• W3072257851 hasAuthorship W3072257851A5091736159 @default.
• W3072257851 hasBestOaLocation W30722578511 @default.
• W3072257851 hasConcept C118487528 @default.
• W3072257851 hasConcept C126322002 @default.
• W3072257851 hasConcept C141071460 @default.
• W3072257851 hasConcept C168563851 @default.
• W3072257851 hasConcept C2776403814 @default.
• W3072257851 hasConcept C2776694085 @default.
• W3072257851 hasConcept C2777802072 @default.
• W3072257851 hasConcept C2778257484 @default.
• W3072257851 hasConcept C2780827179 @default.
• W3072257851 hasConcept C2781100027 @default.
• W3072257851 hasConcept C2781359195 @default.
• W3072257851 hasConcept C44249647 @default.
• W3072257851 hasConcept C68443243 @default.
• W3072257851 hasConcept C71924100 @default.
• W3072257851 hasConceptScore W3072257851C118487528 @default.
• W3072257851 hasConceptScore W3072257851C126322002 @default.
• W3072257851 hasConceptScore W3072257851C141071460 @default.
• W3072257851 hasConceptScore W3072257851C168563851 @default.
• W3072257851 hasConceptScore W3072257851C2776403814 @default.
• W3072257851 hasConceptScore W3072257851C2776694085 @default.
• W3072257851 hasConceptScore W3072257851C2777802072 @default.
• W3072257851 hasConceptScore W3072257851C2778257484 @default.
• W3072257851 hasConceptScore W3072257851C2780827179 @default.
• W3072257851 hasConceptScore W3072257851C2781100027 @default.
• W3072257851 hasConceptScore W3072257851C2781359195 @default.
• W3072257851 hasConceptScore W3072257851C44249647 @default.
• W3072257851 hasConceptScore W3072257851C68443243 @default.
• W3072257851 hasConceptScore W3072257851C71924100 @default.
• W3072257851 hasIssue "10" @default.
• W3072257851 hasLocation W30722578511 @default.
• W3072257851 hasLocation W30722578512 @default.
• W3072257851 hasLocation W30722578513 @default.
• W3072257851 hasOpenAccess W3072257851 @default.
• W3072257851 hasPrimaryLocation W30722578511 @default.
• W3072257851 hasRelatedWork W2000192077 @default.
• W3072257851 hasRelatedWork W2024548441 @default.

• next